Matteo Dal PeraroMatteo Dal Peraro graduated in Physics at the University of Padua in 2000. He obtained his Ph.D. in Biophysics at the International School for Advanced Studies (SISSA, Trieste) in 2004. He then received postdoctoral training at the University of Pennsylvania (Philadelphia) under the guidance of Prof. M. L. Klein. He was nominated Tenure Track Assistant Professor at the EPFL School of Life Sciences in late 2007.
His research at the Laboratory for Biomolecular Modeling (LBM), within the Interfaculty Institute of Bioengineering (IBI), focuses on the multiscale modeling of large macromolecular systems.
Sylvie Roke2011 present: Julia Jacobi Chair in photomedicine, École Polytechnique Fédérale Lausanne (EPFL), CH. 2005 2012: Max Planck Research Group Leader (W2 /C3) of a centrally announced open theme independent research group. Host: The Max-Planck Institute for Metals Research, Stuttgart, DE. 2005 2005: Alexander von Humboldt Fellow, dept. of Applied Physical Chemistry, Heidelberg University, DE. 2004 2005: Postdoctoral Fellow, FOM-Institute for Plasma Physics, NL.
Suliana ManleyFrom 2016 Associate professor, EPFL, Lausanne, Switzerland
2009-2016 Tenure-track assistant professor, EPFL, Lausanne, Switzerland
2006-2009 Post-Doctoral fellow, National Institutes of Health, Bethesda, MD, USA
2004-2006 Post-Doctoral fellow, Massachusetts Institute of Technology, Cambridge, MA, USA
1999-2004 PhD (Physics) Awarded 06/2004, Harvard University, Cambridge, MA, USA
1993-1997 Bachelors (Cum Laude) Physics & Mathematics, Rice University, Houston, TX, USA
Didier TronoAprès des études de médecine à l’Université de Genève et une formation clinique en pathologie, médecine interne et maladies infectieuses à Genève et au Massachusetts General Hospital de Boston, Didier Trono s’engage dans une carrière scientifique au Whitehead Institute du MIT. En 1990, il est recruté par le Salk Institute de San Diego pour lancer un centre de recherche sur le SIDA. Il rentre en Europe sept ans plus tard, avant de prendre en 2004 les rênes de la toute nouvelle faculté des Sciences de la Vie de l’EPFL, dont il orchestre le développement et qu’il dirige jusqu’en 2012. Il participe aujourd’hui activement à la coordination des efforts de la Suisse en vue de l’intégration des nouvelles technologies dans le domaine de la médecine de précision et de la santé personnalisée.
Hilal Lashuel2012-2013 Visiting Professor, Standford University. Stanford School of Medicine
2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Chemical Biology of Neurodegeneration
2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Molecular Neurobiology and Neuroproteomics
2005-2008 Director- EPFL Proteomic Core Facility
2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's
Hospital
2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration
Harvard Medical School,
2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases
Harvard Medical School and Brigham and Women's Hospital
Advisor- Prof. Peter T. Lansbury
2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck
New York
1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute
Advisor- Prof. Jeffery W. Kelly
1990-1994 B.S. City University of New York, Brooklyn College
Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/).
Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.
Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies. Gerardo TurcattiSenior scientific level (R&D) with extensive experience in the management of multidisciplinary technological projects. Prof. Gerardo Turcatti, directs the academic technological platform, Biomolecular Screening Facility (BSF) at the EPFL he created in 2006. In the framework of the NCCR-Chemical Biology, he is project leader of the program ACCESS (An Academic Chemical Screening Platform for Switzerland). Previously he co-founded and acted as CTO of Manteia S.A., a Swiss-based company that developed high throughput DNA sequencing technologies currently owned by Illumina and used in the ‘Next Generation Sequencing’ instruments. Prior to this experience, Prof. Turcatti had a long multidisciplinary career in R&D divisions of Biotechnology and Pharmaceutical companies with extensive expertise in several Chemical Biology-related disciplines such as Drug Screening, Chemical Biology, Bio-analytical Chemistry, DNA and Protein Chemistry. Prof. Turcatti earned his Master in Chemical Engineering at the University of Geneva and his PhD in Chemistry and Biochemistry from the EPFL where he received the award for the best doctoral thesis of the year.
Pamina WinklerJe suis actuellement Postdoctorante dans l'équipe interdisciplinaire de
SuNMIL
. Le but de ma recherche est d'étudier les interactions entre les protéines pour en améliorer notre compréhension, ceci en utilisant des techniques complémentaires.
En tant que représentante de l'Assemblée d'École, je souhaite défendre les intérêts du corps intermédiaire et je m'attelerai à créer un environnement professionnel qui soit inclusif et durable.
Ma mission sera de représenter plus en particulier les intérêts et droits des postdoctorants, comme je suis la responsable du groupe de travail sur les politiques de
l'Association des Postdoctorants de l’EPFL (EPDA)
. De plus, mon objectif sera d'établir des liens solides parmi tous les groupes représentés à l'Assemblée d’Ecole.
